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Quantifying vehicle control from physiology in type 1 diabetes 
Abstract 
Objective: Our goal is to measure real-world effects of at-risk driver physiology on safety-critical tasks like 
driving by monitoring driver behavior and physiology in real-time. Drivers with type 1 diabetes (T1D) have 
an elevated crash risk that is linked to abnormal blood glucose, particularly hypoglycemia. We tested the 
hypotheses that (1) T1D drivers would have overall impaired vehicle control behavior relative to control 
drivers without diabetes, (2) At-risk patterns of vehicle control in T1D drivers would be linked to at-risk, in-
vehicle physiology, and (3) T1D drivers would show impaired vehicle control with more recent 
hypoglycemia prior to driving. 
Methods: Drivers (18 T1D, 14 control) were monitored continuously (4 weeks) using in-vehicle sensors 
(e.g., video, accelerometer, speed) and wearable continuous glucose monitors (CGMs) that measured 
each T1D driver’s real-time blood glucose. Driver vehicle control was measured by vehicle acceleration 
variability (AV) across lateral (AVY, steering) and longitudinal (AVX, braking/accelerating) axes in 
45-second segments (N = 61,635). Average vehicle speed for each segment was modeled as a covariate 
of AV and mixed-effects linear regression models were used. 
Results: We analyzed 3,687 drives (21,231 miles). T1D drivers had significantly higher overall AVX, Y 
compared to control drivers (BX = 2.5 × 10−2 BY = 1.6 × 10−2, p < 0.01)—which is linked to erratic steering 
or swerving and harsh braking/accelerating. At-risk vehicle control patterns were particularly associated 
with at-risk physiology, namely hypo- and hyperglycemia (higher overall AVX,Y). Impairments from 
hypoglycemia persisted for hours after hypoglycemia resolved, with drivers who had hypoglycemia within 
2–3 h of driving showing higher AVX and AVY. State Department of Motor Vehicle records for the 3 years 
preceding the study showed that at-risk T1D drivers accounted for all crashes (N = 3) and 85% of citations 
(N = 13) observed. 
Conclusions: Our results show that T1D driver risk can be linked to real-time patterns of at-risk driver 
physiology, particularly hypoglycemia, and driver risk can be detected during and prior to driving. Such 
naturalistic studies monitoring driver vehicle controls can inform methods for early detection of 
hypoglycemia-related driving risks, fitness to drive assessments, thereby helping to preserve safety in at-
risk drivers with diabetes. 
Keywords 
Diabetes mellitus, driving risk, hypoglycemia, vehicle control 
Disciplines 
Internal Medicine | Neurology | Public Health | Transportation Engineering 
Comments 
This is an Accepted Manuscript of an article published by Taylor & Francis as Chakraborty, Pranamesh, 
Jennifer Merickel, Viraj Shah, Anuj Sharma, Chinmay Hegde, Cyrus Desouza, Andjela Drincic, Pujitha 
Gunaratne, and Matthew Rizzo. "Quantifying vehicle control from physiology in type 1 diabetes." Traffic 
Injury Prevention (2019): 1-6. Available online at DOI: 10.1080/15389588.2019.1665176. Posted with 
permission. 
Authors 
Pranamesh Chakraborty, Jennifer Merickel, Viraj Shah, Anuj Sharma, Chinmay Hegde, Cyrus Desouza, 
Andjela Drincic, Pujitha Gunaratne, and Matthew Rizzo 
This article is available at Iowa State University Digital Repository: https://lib.dr.iastate.edu/ccee_pubs/256 
1 
 
Quantifying vehicle control from physiology in type 1 diabetes 
 
Pranamesh Chakrabortya†, Jennifer Merickelb, Viraj Shahc, Anuj Sharmaa, Chinmay Hegdec, Cyrus Desouzad, 
Andjela Drincicd, Pujitha Gunaratnee, Matthew Rizzob 
a Department of Civil, Construction, and Environmental Engineering, Iowa State University, USA 
b Neurological Sciences, University of Nebraska Medical Center, USA 
c Department of Electrical and Computer Engineering, Iowa State University, USA 
d Internal Medicine, University of Nebraska Medical Center, USA 
e Toyota Collaborative Safety Research Center, USA 
†Corresponding Author: pranameshbesu@gmail.com 
 
Objective: Our goal is to measure real-world effects of at-risk driver physiology on safety-critical tasks like driving 
by monitoring driver behavior and physiology in real-time. Drivers with type 1 diabetes (T1D) have an elevated crash 
risk that is linked to abnormal blood glucose, particularly hypoglycemia. We tested the hypotheses that 1) T1D drivers 
would have overall impaired vehicle control behavior relative to control drivers without diabetes, 2) At-risk patterns 
of vehicle control in T1D drivers would be linked to at-risk, in-vehicle physiology, and 3) T1D drivers would show 
impaired vehicle control with more recent hypoglycemia prior to driving. 
Methods: Drivers (18 T1D, 14 control) were monitored continuously (4-weeks) using in-vehicle sensors (e.g., video, 
accelerometer, speed) and wearable continuous glucose monitors (CGMs) that measured each T1D driver’s real-time 
blood glucose. Driver vehicle control was measured by vehicle acceleration variability (AV) across lateral (AVY, 
steering) and longitudinal (AVX, braking/accelerating) axes in 45-second segments (N = 61,635). Average vehicle 
speed for each segment was modeled as a covariate of AV and mixed-effects linear regression models were used.  
Results: We analyzed 3,687 drives (21,231 miles). T1D drivers had significantly higher overall AVX, Y compared to 
control drivers (BX = 2.5×10-2 BY = 1.6×10-2, p < 0.01)––which is linked to erratic steering or swerving and harsh 
braking/accelerating. At-risk vehicle control patterns were particularly associated with at-risk physiology, namely 
hypo- and hyperglycemia (higher overall AVX,Y). Impairments from hypoglycemia persisted for hours after 
hypoglycemia resolved, with drivers who had hypoglycemia within 2-3 hours of driving showing higher AVX and AVY. 
State Department of Motor Vehicle records for the 3 years preceding the study showed that at-risk T1D drivers 
accounted for all crashes (N = 3) and 85% of citations (N = 13) observed. 
Conclusions: Our results show that T1D driver risk can be linked to real-time patterns of at-risk driver physiology, 
particularly hypoglycemia, and driver risk can be detected during and prior to driving. Such naturalistic studies 
monitoring driver vehicle controls can inform methods for early detection of hypoglycemia-related driving risks, 
fitness to drive assessments, thereby helping to preserve safety in at-risk drivers with diabetes.  
Keywords:  diabetes mellitus, driving risk, hypoglycemia, vehicle control 
INTRODUCTION 
Diabetes is one of the most prevalent diseases worldwide, affecting more than 285 million people and ~6.4% of the 
world population in 2010 (Shaw et al. 2010). By 2030, the prevalence of diabetes is expected to rise to 439 million 
people and 7.7% of the world population. This presents a significant problem of patient and public safety due to 
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elevated vehicle crash risk in drivers with diabetes, compared to drivers without diabetes (Tregear et al. 2017).  At-
risk physiology in diabetes has been linked to this risk. Hypoglycemia (low blood glucose) is a primary factor 
impacting diabetes driver risk, particularly in insulin-dependent type 1 diabetes (T1D) (Cox et al. 2009). Although 
insulin is essential for diabetes patients’ survival, close control over hyperglycemia (high blood glucose) can increase 
the risk of hypoglycemia. Driving licensing authorities of most developed countries make a distinction if a driver with 
diabetes is treated with insulin or not (Graveling and Frier 2015), due to an elevated risk of hypoglycemia with insulin 
treatment.  
 
Severe hypoglycemia (blood glucose < 54 mg/dL) in patients with diabetes leads to the occurrence of neuroglycopenic 
symptoms (weakness or fatigue, confusion, warmth sensation, severe cognitive failure, coma), requiring immediate 
action and treatment to resolve hypoglycemia (American Diabetes Association 2019). However, impairment can also 
occur at less severe levels of hypoglycemia (glucose level < 70 mg/dL) (McCrimmon et al. 2012). In past studies, 
Deary and Zammitt (2014) and Evans et al. (2000) performed detailed analyses of cognitive tests perforrmed on 
recently hypoglycemic T1D patients to determine the timeline of cognitive function recovery post-hypoglycemia. 
Their analysis showed that the cognitive function of T1D patients remained impaired for approximately 75 minutes 
after hypoglycemia. Hypoglycemia affects attention, memory, and decision-making abilities needed for safe driving, 
increasing risk of crashes due to driver error. Research has shown that cognitive impairment due to hypoglycemia, 
even in less severe forms, can affect safe performance in complex, high-risk tasks which requires vigilance, rapid 
response, and hand-eye coordination––such as automobile driving. Compounding this safety risk, driver awareness of 
hypoglycemia varies and some drivers are unaware of hypoglycemia, which may hinder driver ability to adopt 
strategies to mitigate risk from hypoglycemia.   
 
Despite these risks, driver risk from diabetes is poorly understood, particularly its relationship to real-time physiologic 
changes like at-risk glycemia. A critical limitation of previous literature is that driving in diabetes has been primarily 
assessed in controlled, simulator settings (Cox et al. 2000)––where drivers may be in different physiologic states than 
typical and behave differently than they would in the real-world. We overcome these limitations of prior work by 
applying technological advances in in-vehicle and wearable sensor-based technologies to address this problem of 
public health and patient in drivers with insulin-dependent T1D. 
 
Hypotheses 
We tested the hypotheses that 1) Disease status: T1D drivers would have impaired vehicle control behavior relative 
to control drivers without diabetes, 2) In-vehicle physiology: Impaired vehicle control would be linked to acute (in-
vehicle), at-risk physiology  in T1D drivers, and 3) Prior physiology: T1D drivers would show impaired vehicle 
control with more recent hypoglycemia prior to driving.  
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RESEARCH DESIGN AND METHODS 
Data Collection 
Each driver participated in the study for 4 weeks of continuous naturalistic driving data collection (all drivers) and 
physiology (T1D).   
 
Participants 
This study involved a total of 36 participants. Twenty had insulin-dependent T1D and 16 were control drivers who 
had no presence of diabetes, based on self-report or medical exam (T1D drivers, < 12% HbA1c; control drivers, < 
5.7% HbA1c) (American Diabetes Association 2019). Control participants were matched to T1D participants by age 
(within 2 years), gender, education (within 2 years), and typical driving environment (rural vs. urban). All participants 
were legally licensed and active drivers who gave informed consent to the study participation according to institutional 
guidelines. Out of the 36 participants, two control participants were excluded after study consent due to laboratory 
evidence of possible diabetes. One diabetes participant was excluded due to the incompatibility of their vehicle with 
the study’s driving instrumentation. Analyzable data were obtained from 19 T1D drivers and 14 control drivers 
between 21-59 years of age (µ = 33.2 years). Table 1 shows a summary of participant demographics, driving 
experience, and hemoglobin A1c (Hb1Ac) levels. 
 
All participants completed a physical examination and a full medical history at induction. Medical conditions and 
medications that presented a significant confounding effect on driver behavior or are known to worsen diabetes were 
excluded. For examples, patients with kidney failure were excluded because they are not able to process insulin and 
therefore have a high propensity for hypoglycemia (Sandholm et al. 2012). Excluded medical conditions included 
neuropathy, pulmonary disease, major psychiatric disorders, neurologic conditions, vestibular disease, sleep disorders, 
current substance abuse, visual field defects, and thyroid or kidney diseases. Excluded medications were narcotics, 
anxiolytics, anticonvulsants, sedating antihistamines, and major psychoactive medication. All participants had safe 
vision for driving as per the Nebraska Department of Motor Vehicle (DMV) standards (binocular, corrected or 
uncorrected <20/40).  DM drivers had received a diagnosis of T1D, used insulin at least daily, and had self-reported 
at least bi-weekly hypoglycemic episodes.  
 
Laboratory Assessments: All drivers completed a standardized self-reported demographic (e.g., age, gender, 
race/ethnicity, education, and socioeconomics), health (diagnosis history and medication usage), and vision 
assessments (corrected or uncorrected, near/far visual acuity [ETDRS OU] and contrast sensitivity [ETDRS, 2.5% 
OU]) at the start of the study period. Presence of diabetes and basic metabolic function were assessed in all drivers 
via blood labs (e.g., HbA1c, BMP [basic metabolic panel]).  
 
Naturalistic Driving Assessment: Driving data were collected using in-vehicle sensor instrumentation installed in the 
participant’s own vehicle. Driving behavior was remotely and continuously recorded from on- to off ignition in each 
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participant’s own vehicle via “Black Box” vehicle sensor instrumentation, which collected video, accelerometer, GPS, 
speed, throttle, and RPM data at a frequency of 1 Hz. Each driver drove as they typically would for the entire study 
period (4-weeks). In addition to collected naturalistic driving data, state records of crashes and citations were collected 
to quantify each participant’s safety in the 3 years prior to enrollment and to provide insight how driver behavior in 
the study linked to overall safety. 
 
Glucose Data Collection: All DM drivers wore continuous glucose monitors (CGMs) throughout the study period. 
Real-world glucose levels (lows, peaks, and variability) can be obtained directly from CGMs (Klonoff, Ahn, and 
Drincic 2017) and linked to time synchronized driving data collected from in-vehicle sensors. All CGM devices were 
“blinded” so the T1D participants could not use its real-time feedback and treatment. Glucose levels were sampled by 
CGMs every 5 minutes. In addition to wearing the CGM, participants self-sampled their glucose with a glucometer 
twice daily throughout the study, which provided verification of CGM collected glucose levels. CGM data quality 
was determined per FDA recommendations (PMA P120005/S018 2014). Mean difference between CGM and 
glucometer glucose levels was 4.29% (range: 2.8% - 6.55%), well below the FDA required standard of < 25% 
difference between these measurements (PMA P120005/S018 2014). Glucose levels exceeding a change > 25% within 
a 15-minute time span were removed, removing on average 2.1% of CGM data per participant. Overall, T1D 
participants complied with CGM use, with only an average of 5.5% of glucose data missing per participant (range 
1.7% - 10.2%). This well exceeds FDA guidelines for > 75% of data present for usable CGM data. To synchronize 
CGM and driving data, CGM data were first up-sampled (forward-fill interpolation) to match the frequency of driving 
data (from 5 minutes to 1 Hz) and merged by time-stamp. Missing CGM data was not interpolated.  
 
Models 
Vehicle Control Outcomes: Vehicle control was modeled using acceleration variability (AV) across lateral (AVy, 
steering) and longitudinal (AVx, braking/accelerating) axes in 45-second segments (Bishop et al. 2018). Vehicle 
acceleration has been used previously in the literature to identify individual driver patterns (Fung et al. 2017), risky 
driving (Kluger et al. 2014), crashes/crash severity (Stipancic et al. 2018), and driver impairments (Merickel et al. 
2019). Increased AV can be linked to erratic driving, harsh braking and accelerating, poor steering control, lane 
variability, and swerving (Palat et al. 2019). Decreased AV has been linked to attentional impairments, reduced driver 
responsiveness to the environment, and may indicate failure to appropriately adjust the vehicle relative to the roadway 
or other on-road vehicles (Merickel et al. 2019). To calculate AV, each drive was divided into 45-seconds segments 
and AV was calculated using the standard deviation of lateral/longitudinal acceleration values. To permit analysis of 
continuous driving, driving data with speeds < 8 kph (5 mph) were removed when the car was not moving, in dense 
traffic, or coming to a stop. Average vehicle speed for each segment was used as a control variable in models to 
account for differences in AV due to speed. Vehicle control was modeled across driver covariates using mixed-effect 
linear regression models with a by-participant random intercept.  
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Driver Covariates: Driver disease status and glucose conditions were assessed and analyzed as driver covariates. To 
test the 1st hypothesis (disease status), presence of DM among drivers (i.e., T1D drivers or control drivers) was used 
as a categorical variable. To test the 2nd hypothesis (in-vehicle physiology), each T1D drivers in-vehicle glycemic 
state was determined by categorizing CGM data for each drive across 3 categories: hypoglycemic (< 70mg/dL), 
euglycemic (70 - 180 mg/dL), and hyperglycemic (> 180 mg/dL) relative to the most severe blood glucose level 
observed during the drive––as per ADA’s standard (American Diabetes Association 2019). T1D driver in-vehicle 
glycemic state was assessed relative to control driver vehicle control (baseline condition). To test the 3rd hypothesis 
(prior physiology), only euglycemic T1D drivers were used in the model to objectively determine the impact of 
impairment due to prior hypoglycemia without confounding effects of current at-risk glycemia. In addition to each 
driver’s in-vehicle glycemic state, the time since each driver’s most recent hypoglycemic episode prior to the drive 
(in minutes) and the duration of that episode (in minutes) were computed. The overall severity of each prior 
hypoglycemic episode was also assessed. Episodes were classified as severe if glucose fell below < 54 mg/dL durring 
the hypoglycemic episode (American Diabetes Association 2019). Age and gender were used as control variables in 
each model, to account for differences in vehicle control behavior due to driver demographics.  
RESULTS 
Our study data was collected from a total of 848 driver days, 3,687 drives, and 34,168 km (21,231 miles) driving. Out 
of this, T1D drivers’ behavior was reported across 1,940 drives and 16,610 km (10,321 miles). The total drive duration 
was divided into 61,635 segments of 45-seconds duration (28,569 segments from T1D drivers). The mean AVX and 
AVY across all segments for all participants were found to be 0.078 and 0.075 respectively. AVX and AVY were found 
to decrease with the increase in vehicle speed across all the three hypotheses (p < 0.001). However, age and gender 
were not found to be statistically significant in any of the hypotheses (p > 0.05). The detailed results specific to each 
of the three hypotheses are discussed next.   
Disease status 
T1D drivers had higher braking/accelerating and steering changes (increased AVX  and AVY) compared to control 
drivers (BX = 2.5×10-2 BY = 1.6×10-2, p < 0.01)––which is linked to erratic steering or swerving and harsh 
braking/accelerating (Figure 1, Table 2). T1D drivers showed greater reduction in AV on higher speed roadways 
compared to the control drivers (BX = -5.6×10-4, BY = -3.9×10-4, p < 0.001).  
In-vehicle physiology 
T1D drivers who were currently hypoglycemic and hyperglycemic while driving showed higher higher/accelerating 
(increased AVX) (Bhypo = 3.4×10-2, Bhyper = 2.5×10-2, p ≤ 0.001) and increased steering changes (increased AVY) (Bhypo 
= 2.6×10-2, Bhyper = 1.5×10-2, p < 0.01) than control drivers ( 
 
Table 3). However, euglycemic conditions resulted in reduced steering control (decreased AVY) only (Beu = 1.1×10-2, 
p = 0.04) and no statistically significant reduction in braking/accelerating (AVX) were observed (p > 0.05). 
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Prior physiology 
Hypoglycemia prior to a drive resulted in persistent impairments in vehicle control behaviors, even for T1D drivers 
who were euglycemic at time of driving. For up to 2 hours after hypoglycemia resolved, T1D drivers showed decreased 
AVY (B1hour = -1.3×10-3, B2hour = -1.5×10-4, p < 0.05,  
Table 4), which may link to decreased steering changes relative to driving environment dynamics (e.g., traffic). 
Results suggest that after a 2-hour recovery period from hypoglycemia, T1D drivers no longer showed significant 
changes in AVY. (p > 0.05,  
Table 4). Drivers showed less braking/accelerating (decreased AVx) for up to 3 hours since hypoglycemia resolves 
(B1hour = -1.3×10-3, B2hour = -1.5×10-4, B3hour = -1.5×10-4, p < 0.05). Once drivers had at least 3 hours to recover from 
hypoglycemia, braking/accelerating behavior was no longer affected (p > 0.05). While impairments in vehicle control 
persisted after hypoglycemia resolved, they were marginal in effect size compared to the effect of current at-risk 
glycemia. Impairments due to prior hypoglycemia were unaffected by episode duration and severity.  
 
Crash Risk from State Records 
In addition to these analyses and observations obtained from in-vehicle sensor data, State Department of Motor 
Vehicle records for the 3 years preceding the study showed that at-risk T1D drivers accounted for all crashes (N = 3, 
2 at fault) and 85% of citations (N = 13) observed. In concert with our results, this links elevated crash risk in this 
T1D cohort to at-risk physiology, particularly hypoglycemia. 
DISCUSSION 
Our results link disease and at-risk physiology to impaired vehicle control in T1D. T1D drivers show impaired vehicle 
control related to steering, accelerating, and braking variability compared to drivers without diabetes. These 
impairments are elevated during at-risk physiologic states. Vehicle control impairments are linked to environment, 
with T1D drivers showing greater differences in behavior relative to control drives during higher-speed driving. This 
may link to elevated crash severity due to risk on high-speed roadways. This is noteworthy in as much as crash severity 
is greater on high-speed roadways. 
 
Our results are consistent with prior studies suggesting that vehicle control impairments due to hypoglycemia may 
persist for hours after hypoglycemia resolves (Weinger et al. 1999; Merickel et al. 2019), even in T1D drivers whose 
blood glucose levels are currently normal. We find that impairments due to prior hypoglycemia affect vehicle control 
behavior for 2-3 hours after hypoglycemia resolves, which provides an important foundation for developing objective, 
clinical recommendations to preserve safety in at-risk drivers with diabetes. Importantly, our results suggest that 
impairments from hypoglycemia may persist for longer in complex, real-world tasks like driving than based on 
laboratory-based cognitive examination (Evans et al. 2000; Deary and Zammitt 2014; Zammitt et al. 2008). While 
braking/accelerating and steering were effected by prior hypoglycemia, steering-related impairments from prior 
hypoglycemia persisted for longer than braking/accelerating-related impairments––suggesting that the cognitive 
mechanisms and associated impairments from hypoglycemia vary relative to the particular vehicle control behavior.  
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Admittedly, further research is needed to map the patterns of vehicle control we observe in this study to quantitative 
metrics of driver risk. Video validation can provide key insights linking real-world driving risks scenarios such as lane 
incursions, reduced response time to lead vehicle braking, etc. to cognitive impairment related to hypoglycemia. Also, 
it can provide greater understanding of the different scenarios and driver distractions that might lead to variability in 
driving in addition to hypoglycemia related cognitive impairment. While this study focused on driver control behavior 
under continuous driving situations, it can be extended in future to include complex driver behavior that can be 
observed at traffic intersections, stop signs, or congested traffic conditions. Driver risk can be also associated in future 
to understand its relation to the frequency of hypoglycemic episodes, T1D disease progression, and other factors 
impacting T1D driver risk. Such detailed analysis can be feasible by observing a larger sample of T1D patients with 
healthy drivers encompassing a wider variety and uniform representability of the entire population.   
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Table 1. Summary of participant demographic characteristics, driving experience, and DM presence (HbA1c) 
Participant 
Type Age (years) Gender Race 
Driving 
Experience 
(Years) Hb1Ac 
T1D Range: 21-52 Female: N = 12 
Male: N = 7 
White: 
N = 19 
Range: 6-36 Range: 6.5-11.3 
µ = 32.5 µ = 16.1 µ = 7.7 
SD = 9.6 SD = 9.5 SD = 1.06 
Control Range: 21-55 Female: N = 10 
Male: N = 4 
White: 
N = 13 
Asian: N = 1 
Range: 4-33 Range: 4.7-5.9 
µ = 32.3 µ = 15.1 µ = 5.3 
SD = 10.4 SD = 9.8 SD = 0.30 
 
 
Table 2. Effect of disease status (T1D or control drivers) on AVX and AVY 
Variable 
AVX AVY 
Coef. (B) p Coef. (B) p 
Intercept 0.143 < 0.001 0.137 < 0.001 
Speed (kph) -7.4×10-4 < 0.001 -7.0×10-4 < 0.001 
DM patient     
        No (Control Driver, ref) - - - - 
       Yes (T1D) 2.5×10-2 0.001 1.6×10-2 0.002 
Interaction Term (Speed:DM)     
       Speed:No (ref) - - - - 
       Speed:Yes (T1D) -3.5×10-4 < 0.001 -2.4×10-4 < 0.001 
 
 
Table 3. Effect of current physiologic conditions on AVX and AVY 
Variable 
AVX AVY 
Coef. (B) p Coef. (B) p 
Intercept 1.43×10-1 < 0.001 1.37×10-1 < 0.001 
Speed (mph) -7.4×10-4 < 0.001 -7.0×10-4 < 0.001 
Blood Glucose Level     
       Control Driver (ref) - - - - 
       Hypoglycemic (T1D) 3.4×10-2 < 0.001 2.6×10-2 < 0.001 
       Hyperglycemic (T1D) 2.5×10-2 0.001 1.5×10-2 0.002 
       Euglycemic (T1D) 1.4×10-2 0.06 1.1×10-2 0.04 
Interaction Term (Speed:Blood Glucose)     
       Speed:Control (ref) - - - - 
       Speed:Hypoglycemic (T1D) -4.9×10-4 < 0.001 -3.7×10-4 < 0.001 
       Speed:Hyperglycemic (T1D) -2.2×10-4 < 0.001 -1.9×10-4 < 0.001 
       Speed:Euglycemic (T1D) -3.6×10-4 < 0.001 -2.5×10-4 <  .001 
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Table 4. Effect of time since hypoglycemia on AVX and AVY 
Max. Time since 
hypoglycemia 
Segments 
(n) Variable 
AVX AVY 
Coef. (B) p Coef. (B) p 
1 hour 197 
Intercept 2.3×10-1 < 0.001 2.4×10-1 < 0.001 
Speed (mph) -1.7×10-3 < 0.001 -1.4×10-3 < 0.001 
Time since hypoglycemia (mins) -4.3×10-4 0.18 -1.3×10-3 0.001 
2 hours 728 
Intercept 1.9×10-1 < 0.001 1.7×10-1 < 0.001 
Speed (mph) -1.2×10-3 < 0.001 -1.1×10-3 < 0.001 
Time since hypoglycemia (mins) -1.7×10-4 0.002 -1.5×10-4 0.03 
3 hours 1358 
Intercept 1.8×10-1 < 0.001 1.6×10-1 < 0.001 
Speed (mph) -1.2×10-3 < 0.001 -1.0×10-3 < 0.001 
Time since hypoglycemia (mins) -5.9×10-5 0.02 -4.5×10-5 0.19 
4 hours 2247 
Intercept 1.7×10-1 < 0.001 1.6×10-1 < 0.001 
Speed (mph) -1.8×10-3 < 0.001 -9.7×10-4 < 0.001 
Time since hypoglycemia (mins) -1.3×10-6 0.92 -1.6×10-6 0.92 
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Figure 1. Variation of (a) AVX and (b) AVY for DM patients and control drivers 
 
